MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent Highlights Total revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarterU.S. revenue for the fourth ...

Core Viewpoint - Inspira Technologies has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its ordinary shares have been trading below $1.00 for the last 30 consecutive business days [1][2]. Compliance and Trading Status - The notification does not immediately affect the listing or trading of the Company's ordinary shares, which will continue to trade under the symbol "IINN" on The Nasdaq Capital Market [2]. - The Company has a compliance period of 180 calendar days, until August 10, 2026, to regain compliance by ensuring the closing bid price is at least $1.00 for a minimum of ten consecutive business days [2][3]. Potential for Additional Compliance Period - If compliance is not regained by August 10, 2026, the Company may qualify for a second 180-calendar day compliance period, provided it meets other listing requirements and notifies Nasdaq of its intention to cure the deficiency [3]. Monitoring and Future Actions - The Company plans to monitor the closing bid price of its ordinary shares and will consider options to regain compliance within the compliance period [4]. Company Overview - Inspira Technologies is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products including the INSPIRA™ ART100 system and the upcoming INSPIRA ART500 system [5]. - The Company is also developing the HYLA™ blood sensor platform for continuous, non-invasive monitoring, positioning itself as a significant player in the life-support and MedTech sectors [5].

Core Insights - AVITA Medical reported financial results for Q4 and full year 2025, indicating a year of stabilization and a shift towards execution-focused growth in 2026 [1][4]. Fourth Quarter 2025 Financial Highlights - Total revenue for Q4 2025 was $17.6 million, a decrease of 4% from $18.4 million in Q4 2024, primarily due to reimbursement headwinds [6][7]. - Gross profit margin was 81.2%, down from 87.6% in Q4 2024, influenced by product mix and inventory adjustments [8]. - Operating expenses decreased by 5% to $24.7 million compared to $26.1 million in Q4 2024, reflecting a lower cost base [9]. - Net loss for Q4 2025 was $11.6 million, or a loss of $0.38 per share, compared to a loss of $11.6 million, or $0.44 per share in Q4 2024 [12]. Full-Year 2025 Financial Highlights - Total revenues for 2025 increased by 11% to $71.6 million from $64.3 million in 2024, driven by deeper penetration in customer accounts and new product launches [13]. - Gross profit margin for the full year was 82.1%, down from 85.8% in 2024, primarily due to product mix and higher inventory reserves [14]. - Total operating expenses for 2025 were $101.4 million, a decrease of 9% from $111.8 million in the prior year [15]. - Net loss for the full year was $48.6 million, or a loss of $1.74 per share, compared to a net loss of $61.8 million, or $2.39 per share in 2024 [16]. Business Updates and Future Guidance - The company expects full-year 2026 revenue in the range of $80 to $85 million, representing growth of approximately 12% to 19% compared to 2025 [5]. - In January 2026, the company refinanced its existing debt under a new credit facility with Perceptive Advisors, securing up to $60 million to strengthen its capital structure [17][18]. - As of January 2026, six of the seven Medicare Administrative Contractors have published payment rates for RECELL, alleviating a key constraint on utilization experienced in 2025 [6]. - The company is focused on disciplined cash management and accelerating commercial momentum across its core U.S. burn and trauma center opportunities [19].

Core Viewpoint - Anika Therapeutics, Inc. will release its fourth quarter and year-end 2025 financial results on February 26, 2026, followed by a conference call to discuss the results and business highlights [1]. Group 1: Financial Results Announcement - The financial results will be issued before the market opens on February 26, 2026 [1]. - A conference call is scheduled for 8:30 a.m. ET on the same day to discuss the results [1]. Group 2: Conference Call Access - The conference call can be accessed via a toll-free domestic number (1-800-717-1738) or an international number (1-646-307-1865) with the conference ID number 89327 [2]. - A live audio webcast and presentation materials will be available on Anika's Investor Relations website [2]. - The call will be archived and accessible shortly after its conclusion on the same website [2]. Group 3: Company Overview - Anika Therapeutics, Inc. is a global joint preservation company focused on early intervention orthopedic care [3]. - The company specializes in hyaluronic acid and implant solutions, partnering with clinicians to provide minimally invasive products [3]. - Anika targets high opportunity areas within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, with products delivered in key care sites like ambulatory surgery centers [3]. - The company's global operations are headquartered outside of Boston, Massachusetts [3].

("Charming†or the "Company†) (NASDAQ: MCTA) securities between October 10, 2025 and November 12, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CHARMING MEDICAL LIMITED (MCTA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PA...## Deadline Approaching: China Liberal Education Holdings Limited (CLEUF) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithBENSALEM, Pa.--([BUSINESS WIRE])--Law Offices of Howard G. Smith reminds investors of the upco ...

Core Insights - West Pharmaceutical Services, Inc. (WST) reported adjusted fourth-quarter 2025 earnings per share (EPS) of $2.04, a 12.1% increase year over year, exceeding the Zacks Consensus Estimate by 11.5% [1] - The company achieved revenues of $805 million in the fourth quarter, reflecting a 7.5% year-over-year growth, surpassing the Zacks Consensus Estimate by 1.4% [2] - Full-year 2025 revenues reached $3.07 billion, marking a 6.3% increase from 2024, with organic revenues up 4.3% year over year [3] Financial Performance - Adjusted EPS for the full year was $7.29, an 8% increase from 2024 [1] - GAAP EPS for the fourth quarter was $1.82, a 2.2% improvement from the previous year [1] - Gross profit for the quarter increased by 11.1% to $303.9 million, with a gross margin expansion of 130 basis points to 37.8% [10] Segment Performance - Proprietary Products segment reported revenues of $661.8 million, up 7.8% year over year, with high-value products accounting for 48% of net sales [7][8] - Contract-Manufactured Products segment revenues totaled $143.2 million, reflecting a 6.2% year-over-year increase [9] Guidance and Outlook - For Q1 2026, WST expects sales between $770 million and $790 million, with EPS projected in the range of $1.65-$1.70 [14] - Full-year 2026 revenues are anticipated to be between $3.21 billion and $3.27 billion, with organic net sales expected to grow 5-7% [15] - Adjusted EPS for 2026 is projected to be in the range of $7.85-$8.20 [16] Strategic Insights - The company attributes its strong performance to consistent execution of its growth strategy, particularly in the high-value product segment [18] - Management expects the momentum to continue into 2026, focusing on operational discipline and growth sustainability [18] - The guidance reflects steady demand fundamentals and favorable currency tailwinds [19]

Core Viewpoint - Richtech Robotics Inc. is facing a securities fraud lawsuit following misleading statements regarding its collaboration with Microsoft, which led to significant stock price fluctuations during the specified class period [1]. Group 1: Company Overview - Richtech Robotics Inc. (NASDAQ: RR) announced a collaboration with Microsoft's AI Co-Innovation Labs on January 27, 2026, which resulted in a 44.6% increase in stock price [1]. - The company subsequently faced a stock price drop of $1.06, or 20.9%, to close at $4.02 per share on January 29, 2026, after a report indicated that the collaboration was merely a standard customer program without commercial elements [1]. Group 2: Legal Proceedings - A class action lawsuit has been filed on behalf of investors who purchased Richtech securities between January 27, 2026, and January 29, 2026, with a deadline of April 3, 2026, to file a lead plaintiff motion [1]. - The lawsuit alleges that Richtech made materially false and misleading statements about its business and operations, specifically regarding the nature of its relationship with Microsoft [1].

Core Insights - Stryker (SYK) has launched the T2 Alpha Humerus Nailing System, aimed at simplifying surgical procedures for humeral fracture fixation and enhancing patient care consistency [1][4]. Product Overview - The T2 Alpha Humerus Nailing System improves surgeons' management of complex humeral fractures by providing increased procedural flexibility and builds on Stryker's collaboration with surgeons [2][4]. - The system utilizes Stryker's SOMA technology to manage complex fractures, including non-unions and malunions, featuring an anatomically informed nail design for better alignment and fixation stability [7][10]. - It allows for active intraoperative compression of up to 6 mm for controlled fracture reduction and offers multiplanar screw fixation for enhanced stability [11]. Market Performance - Following the announcement of the new system, SYK shares increased by 0.7%, although the stock has seen a 3.4% decline over the past six months, contrasting with an 11.6% decline in the industry and a 9.8% rise in the S&P 500 during the same period [3]. Long-term Outlook - The launch is expected to strengthen Stryker's trauma and orthopedics portfolio, potentially leading to increased procedure volumes and sustained demand in hospital settings, thereby supporting revenue growth and competitive differentiation in the orthopedic trauma market [4][9]. - The trauma and extremities devices market is projected to reach $16.55 billion by 2026, with a CAGR of 5.2% through 2034, driven by the rising prevalence of orthopedic disorders and advancements in less invasive surgical techniques [12].

Core Insights - Baxter reported a fourth-quarter adjusted EPS of 44 cents, which was below management guidance of 52-57 cents and Wall Street estimate of 54 cents, primarily due to an unfavorable product mix [1] - The company achieved sales of $2.974 billion, representing an 8% year-over-year increase on a reported basis and a 3% increase on an operational basis, surpassing the consensus estimate of $2.824 billion [1] Sales Performance - Medical Products & Therapies segment sales were approximately $1.39 billion, increasing by 6% on a reported basis and 4% on an operational basis, driven by higher sales in the Infusion Therapies & Technologies division and strong global demand for Advanced Surgery products [3] - Healthcare Systems & Technologies segment sales reached $827 million, up 5% on a reported basis and 4% on an operational basis, reflecting demand for Care & Connectivity Solutions products and growth in the Front Line Care division [4] - Pharmaceutical sales totaled approximately $668 million, an increase of 4% on a reported basis and 2% on an operational basis, with continued strength in Drug Compounding partially offset by reduced sales in Injectables & Anesthesia [4] Management Commentary - The CEO emphasized that while sales growth was achieved across all segments, the fourth-quarter results did not meet expectations, highlighting the need for continuous improvement and the introduction of a new operating model aimed at simplifying the organization and enhancing performance [5] Future Guidance - Baxter expects fiscal 2026 adjusted earnings to be between $1.85-$2.05 per share, compared to the consensus of $2.25, with an adjusted operating margin projected between 13%-14% [6] - The company forecasts 2026 sales to be between $11.24 billion and $11.36 billion, slightly below the consensus of $11.31 billion, with expected sales growth flat to an increase of 1% [6] Stock Performance - Baxter shares were down 15.6% at $18.79 at the time of publication, trading near its 52-week low of $17.4 [7]

Core Insights - Abbott Laboratories has raised its quarterly dividend to $0.63, marking a 6.8% increase from the previous rate, with a free cash flow payout ratio of 60.4% [1][2] - The company has a consistent dividend growth streak of 13 years, with total annual payout increasing from $1.04 in 2016 to $2.36 in 2025, representing a 127% increase [1] - Despite a 9.8% decline in shares year-to-date, the current dividend yield of 2.14% is considered attractive for income investors [1] Dividend Growth - Abbott has increased its dividend for 13 consecutive years, with a compound annual growth rate of 9.2% over the past decade [1] - The recent quarterly increase from $0.59 to $0.63 continues the trend, although growth rates have moderated compared to earlier in the decade [1] - CEO Robert Ford reaffirmed the company's commitment to growing dividends during the recent earnings call [1] Cash Flow Coverage - In fiscal 2024, Abbott generated $8.56 billion in operating cash flow and $6.35 billion in free cash flow, with a 60.4% free cash flow payout ratio [1] - The payout ratio increased from 42.4% in 2022, reflecting both growing dividend commitments and declining cash generation due to reduced COVID-related testing revenue [1] - Quarterly free cash flow payout ratios showed volatility, with a peak of 110% in Q1 2025, but normalized in subsequent quarters [1] Profitability Metrics - Abbott maintains a 22% operating margin and a 14.7% profit margin, with a return on equity of 13.2%, supporting dividend sustainability [1] - The FreeStyle Libre glucose sensor recall, classified as a Class I recall, poses risks to profitability and may lead to litigation costs [1] - The medical devices segment showed a 12.3% growth in Q4, with strong performance from electrophysiology products [1] Forward Guidance - Management's guidance for 2026 includes an adjusted EPS of $5.55-$5.80, indicating approximately 10% growth at the midpoint [1] - Expected organic sales growth is projected at 6.5-7.5%, with annual margin expansion of 50-70 basis points [1] - The nutrition segment, which declined 8.9% in Q4, is anticipated to face challenges in the first half of 2026 before recovery [1] Valuation and Peer Comparison - Abbott's trailing P/E ratio is 30x, while the forward P/E is 20x, suggesting potential normalization as earnings grow [2] - Compared to Johnson & Johnson's 2.16% dividend yield and 46.6% payout ratio, Abbott's 63.8% payout ratio indicates less cushion but remains sustainable [2] - Institutional investors hold 81.7% of Abbott's shares, reflecting confidence in the company's long-term prospects despite current challenges [2]